ELI LILLY & Co is 81.1x more valuable than BridgeBio Pharma, Inc. by market capitalization ($1.070 T vs $13.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BBIO | LLY |
|---|---|---|
| Market cap | $13.20 B | $1.070 T |
| US-listed rank | #791 | #10 |
| Revenue (latest FY) | $502.08M | $65.18B |
| Net income (latest FY) | - | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 777 | 989 |
ELI LILLY & Co is 81.1x more valuable than BridgeBio Pharma, Inc. by market capitalization ($1.070 T vs $13.20 B).
In their latest fiscal years, BridgeBio Pharma, Inc. reported $502.08M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: BridgeBio Pharma, Inc. and ELI LILLY & Co, or browse the full rankings.